Related Experiment Videos
[Effect of nootropic agents on serum biochemical indices in intellectually deficient children]
Insights
Lactate dehydrogenase (LDH) levels and isoenzyme patterns before treatment can predict the effectiveness of piracetam and nootropil in children with intellectual disabilities. Metabolic analysis aids in assessing nootropic drug efficacy.
Area of Science:
- Biochemistry
- Neuroscience
- Pediatrics
Context:
- Investigating the efficacy of nootropic drugs like piracetam and nootropil in pediatric patients with intellectual disabilities.
- Examining the role of metabolic factors in predicting therapeutic response to cognitive enhancers.
Purpose:
- To determine if pre-treatment metabolic profiles, specifically lactate dehydrogenase (LDH) activity and isoenzyme patterns, correlate with the therapeutic outcomes of piracetam and nootropil.
- To explore the prognostic significance of LDH metabolism in assessing the efficacy of nootropic treatments in children.
Summary:
- Therapeutic outcomes of piracetam and nootropil in children with intellectual disabilities are significantly influenced by pre-existing metabolic profiles, particularly the activity and isoenzymic spectrum of lactate dehydrogenase (LDH).
- Specific combined changes in LDH activity and its isoenzymes, reflecting aerobic and anaerobic metabolic balance, were identified as key determinants of treatment response.
- Experimental studies in rats corroborated the importance of considering individual patient metabolism when administering nootropic agents.
Impact:
- Suggests that assessing LDH metabolic profiles alongside clinical status can provide prognostic insights into the effectiveness of nootropic drug therapy.
- Highlights the potential for personalized medicine approaches in treating cognitive impairments by tailoring treatment based on individual metabolic characteristics.
- Provides a biochemical marker for predicting treatment success, potentially optimizing therapeutic strategies for children with intellectual disabilities.
Abstract:
It was shown that a marked therapeutic effect or its absence in the piracetam and nootropil treatment of children with different degrees of mental retardation is largely determined by the presence in patients' metabolism (before treatment) of certain combined changes in the general activity of lactate dehydrogenase (LDH) and its isoenzymic spectrum with regard to the ratio between aerobic and anaerobic subunits. Experimental studies on rats support the necessity of taking into account patients' metabolism when prescribing nootropic agents. It is suggested that considering LDH changes (along with the clinical condition of patients) may be of prognostic significance in the efficacy assessment of treatment with nootropic drugs.